Compare Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Tax Managed Fund FTSE Developed Markets ETF vs Viatris Inc — how do they compare? Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.05, while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc pays a 2.89% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Viatris Inc nearer its low. Which is the better fit depends on your goals.
| VEA | VTRS | |
|---|---|---|
52-Week High | $73.79 | $17.86 |
52-Week Low | $58.90 | $9.49 |
Market Cap | — | $19.09B |
Sector | — | Health |
Enterprise Value | — | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vanguard FTSE Developed Markets ETF (VEA) trades at $73.46, down 0.41% on the day but near its 52-week high of $74.04. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. Recent news highlights increased institutional buying, such as Allianz Asset Management boosting its stake by 11.8% in Q2 2026 (Defense World, 2026-09-09). The ETF offers low-cost exposure to developed international markets, with an expense ratio of 0.03% (The Motley Fool, 2026-08-20).
VEA's outlook is supported by institutional accumulation and cost efficiency, but risks include concentration in developed markets missing emerging growth. Proximity to the 52-week high suggests limited near-term upside without broader international market momentum. Investors benefit from diversification outside the U.S., though currency fluctuations and geopolitical events pose headwinds.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
